In summary, identifying the PHF23/ACTN4/ERK axis provides a complementary and comprehensive understanding of NSCLC and presents an opportunity to translate fundamental research into potential treatments in clinical practice (Fig. 9). This evidence concerns the gene ACTN4 and non-small cell lung carcinoma.